HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Medical Device Bottleneck Will Have 'Serious Implications' For German Industry, Says BAH’s Dr Cranz

Executive Summary

In an exclusive interview with HBW Insight, the German Medicines Manufacturers´ Association’s (BAH’s) new director general Dr Hubertus Cranz warns of a potentially costly bottleneck forming as German manufacturers scramble to re-certify their self-care medical devices before the May 2020 European Union's new Medical Device Regulations deadline. Dr Cranz also explains how BAH is supporting the country's community pharmacists to help German consumers to self-care safely and responsibly. 

You may also be interested in...

Bayer Stands By Iberogast As German Court Investigates Manslaughter Case

Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”  

German Industry Tries To Nip Homeopathy Debate In The Bud As France Decides In Favour Of De-Reimbursement

As France decides to de-reimburse homeopathic medicines, discussions about whether this should be applied to Germany are being re-opened by politicians and high-profile representatives from the country's statutory health insurance system. Industry has responded by saying "no" to de-reimbursement, as the German system allows consumers to choose between insurers based on their views of homeopathy. 

German Switch Committee Meets: Sumatriptan Goes Again, Antihistamine Reverse-Switch Rejected, For Now

Germany’s Expert Committee for Prescription recommends prescription-to-OTC reclassifications of sumatriptan for migraines and liquid ibuprofen, but rejects an OTC switch for ketoprofen and the reverse-switch of sedative antihistamines for over 65s.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts